Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimotuzumab, Camrelizumab, and Neoadjuvant Chemotherapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
NCT07312578Phase 2Enrolling by invitation
- Sponsor
- Peking University
- Start
- Nov 2025
- Primary completion
- Nov 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of nimotuzumab in Esophageal Squamous Cell Carcinoma (ESCC) (2 arms), sponsored by Peking University. Primary endpoint: Pathological complete response rate up to 2 years. Started Nov 2025; status: enrolling by invitation.
02
Drugs
nimotuzumab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07312578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07312578.